Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 10Lymphoid 8Myeloid 2Classical hematology 2Tumor-Agnostic 1Plasma cell 1Gastrointestinal 1CNS 1

Conditions

Multiple Myeloma 118Myelodysplastic Syndromes 37Hodgkin Disease 35Leukemia, Myeloid, Acute 33Lymphoma 31Lymphoma, Non-Hodgkin 30Neoplasms, Plasma Cell 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia 26Leukemia, Lymphocytic, Chronic, B-Cell 23Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Myeloproliferative Disorders 19Hematologic Neoplasms 18Primary Myelofibrosis 17Recurrence 12Anemia, Aplastic 12Lymphoma, Follicular 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Lymphoma, B-Cell, Marginal Zone 9Hematologic Diseases 9Burkitt Lymphoma 9Leukemia, Prolymphocytic 8Leukemia, Plasma Cell 8Leukemia, Myelomonocytic, Chronic 8Anemia, Refractory, with Excess of Blasts 6Polycythemia Vera 4Ovarian Neoplasms 4Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3

Interventions

Lenalidomide 5Dexamethasone 4fludarabine phosphate 2daratumumab 2Whole-Body Irradiation 2Cyclophosphamide 2Calcium Dobesilate 2talquetamab 1selinexor 1ixazomib 1isatuximab 1fludarabine 1Transplantation, Autologous 1Sirolimus 1Rituximab 1Mycophenolic Acid 1Melphalan 1Bortezomib 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × fludarabine × Plasma cell × Clear all
NCT03524235 2024-11-12

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Cedars-Sinai Medical Center

Phase 1 Completed
20 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡